Ra­dius fal­ters af­ter a PhI­II os­teo­poro­sis fail and a breast can­cer dis­ap­point­ment, send­ing shares plum­met­ing

Ra­dius Health saw shares tank on Wednes­day af­ter re­port­ing two Phase III study re­sults, one for an os­teo­poro­sis patch treat­ment that failed and one for a breast can­cer ther­a­py show­ing low­er ef­fi­ca­cy re­sults than ex­pect­ed.

The biotech is look­ing to de­vel­op a patch ver­sion of its in­jectable Tym­los drug for os­teo­poro­sis in post­menopausal women, but the treat­ment missed its pri­ma­ry end­point and did not show non-in­fe­ri­or­i­ty rel­a­tive to the ap­proved in­jec­tion. Ra­dius is still an­gling to de­vel­op the treat­ment, but ex­ecs said in an in­vestor call it would cause at least a two-year de­lay.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER